Introduction of biosimilars: For a global pharmaceutical company, CRA assessed impact of the introduction of biosimilars, the likely impact on competition and the strategic option this created.
Response to regional tenders of biologics: CRA was asked to help a company respond to the increasing spread of tenders across therapeutic classes, to regional and national payers poses challenges in co-ordinating company responses, maintaining internal price corridors.
Healthcare reform: A major health insurer asked CRA to anticipate the most likely outcome from healthcare reform efforts in the US and to provide advice on how to best prepare for policy changes.
Value-based pricing: For a global pharmaceutical company, CRA assessed the degree to which local and regional payers were interested in the development of VBP, had the appropriate infrastructure and the degree to which these were commercially viable.
Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and delivering often-iterative, sometimes-significant...